Coartem has been the mainstay of frontline malaria therapy since it was introduced in 1999 and more than a billion doses of the drug have been provided by Novartis since then, mostly on a no ...

Now – over a billion doses of Coartem (artemether-lumefantrine) later – the drugmaker thinks it may have developed a new drug that could provide a new option for the disease, which killed more ...